What You Should Know:
– Veradigm (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced a significant expansion of its Veradigm Network EHR (VNEHR) Data with the integration of social determinants of health (SDoH) and mortality data.
– The enhancement provides researchers with a more comprehensive view of patient health, enabling deeper insights and driving innovation in life science research, public health, and academic studies.
VNEHR Data Background
VNEHR Data is one of the nation’s most comprehensive ambulatory electronic health record (EHR) databases. By leveraging advanced natural language processing (NLP) technology, Veradigm extracts valuable information from unstructured data, such as clinical notes, which often contain critical patient information. This enriched dataset empowers researchers to gain a more holistic understanding of patient journeys and outcomes.
Incorporating Social Determinants of Health
The addition of NLP-derived SDoH data provides valuable insights into the socioeconomic, environmental, and behavioral factors that influence health outcomes. This includes information on income levels, education, housing stability, and social support – factors often overlooked in traditional clinical data.
Benefits for Life Science Organizations
The enriched VNEHR Data offers several benefits for life science organizations:
- Enhanced treatment insights: Understanding how SDoH factors influence treatment response and outcomes.
- Advanced evidence generation: Conducting more robust real-world evidence (RWE) studies.
- Improved market access strategies: Developing targeted strategies to reach specific patient populations.
- Refined patient segmentation: Identifying and segmenting patients based on a wider range of factors.
Enhancing Research with Mortality Data
The integration of ambulatory EHR mortality data provides valuable insights into patient populations and outcomes within outpatient settings. This data enables life science organizations to:
- Enhance RWE generation: Demonstrate long-term safety and efficacy of treatments.
- Support post-market surveillance: Identify mortality trends associated with drug or device use.
- Accelerate drug development: Improve the identification of at-risk patient populations.
- Demonstrate value to payers: Provide evidence to support reimbursement decisions.
- Enhance precision medicine: Combine mortality data with genetic and biomarker information for more targeted treatments.
“With our NLP-derived SDoH and mortality data, life sciences organizations gain a competitive advantage by moving beyond traditional clinical measures to explore the full spectrum of factors influencing patient health,” said Stuart Green, Vice President & General Manager of Life Sciences Business for Veradigm. “This innovation unlocks new research opportunities and can position organizations as leaders in advancing health equity and improving patient outcomes.”
